2seventy bio and BMS stop Phase-3-Studie and erwarten Einsparungen from Investing.com

CAMBRIDGE, Mass. – 2seventy bio, Inc. (NASDAQ:TSVT) and Bristol Myers Squibb (NYSE:BMY) have announced the completion of recruitment for the Phase 3 KarMMa-9 trial, which is being conducted by Abecma investigators in combination with lenalidomid retention therapy in newly diagnosed multiple myeloma (NDMM) patients who are suboptimal for autologous stem cell transplantation.

During this separation, 270 biographies were offered in the course of the 80s Millions of US dollars and a cutback path to profit in the year 2025 for the study that is being carried out as an early adoption.

The study halts have led to 270 bio-studies being conducted on Abecma’s US dollar and a quarter of its shares rising 30% to $54 million in two quarters. If the follow-up question to Abecma, the number of new patients who are undergoing apheresis is negligible, the comparison to the previous quarter is a weak waiting list.

Abecma, a B-Zell-Refiring Antigen (BCMA)-targeted, genetically modified autologous T-Zell immunotherapy, is indicated for adult patients with relapsed or refractory multiple myeloma after at least two previous therapies. The therapy is characterized by a different safety profile and a legally valid effectiveness, especially in combination with effective bridging therapies.

Chip Baird, CEO of 2seventy Biography, shows the commitment of the employees to the healthcare and the maintained focus there, Patients more time for care. Anna Truppel-Hartmann, Chief Medical Officer, thanked the patients, families, doctors and study workers who were good at the study.

2seventy biography and Bristol Myers Squibb talk about the victory and delight in the business world with the Entwicklung, Herstellung and Vermarktung of Abecma in the US. Both Unternehmen bleiben der Ausweitung der Verfügbarkeit von Abecma für Patients met multiplem Myelom verpflichtet.

This focuses on a press conference and a mirror of the active developments and forecasts of the financing strategies and an alternative strategy of 2 seventy bios and Bristol Myers Squibb more broadly.

In others, 2Seventy Bio’s Q2 2024 news is active. The earnings call is very valuable and the focus on the ABECMA product lags behind. The internal investigation is a moderation of care and a concern of patients in the apheresis for ABECMA, with a reduction in costs of 28 million dollars. When a trade sum of 4.4 million US dollars was spent with Bristol-Myers Squibb and the FDA treatment for the treatment of patients in the new therapies was carried out the Leistung of ABECMA in the US market.

For the 2Seventy Bio payments, the costs have been reduced to the year 2025 and a net cash consumption forecast for 2024 of US$40 and 60 million has been forecast. If companies are aware of ABECMA in the coming months, it will grow again. If you are on the beach, it is the case that the independence forecasts for ABECMA sales and updates for the Regeneron pipeline asset time plan are generated.

Analysts have done a good analysis of the fact that there are a few ideas about the specific specifications of the expected predictions and pipeline updates. Other studies that look like the positive aspects of the Sicherheitsprofils of ABECMA are based on the FDA guidelines and the clinical studies that show significant progression-free results and indicate a Wirksamkeit.

InvestingPro Insights

The insight into the strategic analysis of the 2seventy bio, the KarMMa-9-Study study, is a better analysis of the financial finance and the market analysis of the external partner context for investors. According to InvestingPro-Daten 2seventy bio, Inc. (NASDAQ:TSVT) has a market capitalization of approximately 246.68 million US dollars, a position in the biotech sector was taken. Analysts for the years that had followed an investment strategy for a year, which had given the liquid assets of 2seventy bio their pure lighting effects, were in the phase of a strategic new direction for a certain financial stability that could be achieved.

The trading movements of the unternehmens were volatile, with a remarkable display of 26.86% in the third month. It may be that the investments of the investors in the long term of the American economies have undergone some herausforderungen behind. If you can no longer use the InvestingPro-Tips, you can not use your money profitably in those years and wage an unprofitable war in the last month. This knowledge of the matter is one of the most important investments for investors, the Leistungsentwicklung of the Unternehmens is examined.

With a short-term profit ratio (SRR) of -1.55 and a final SRR for the last month of Q2 2024 of -1.47, the Company’s performance rating reflects the same unprofitable broader range. The short-term profit ratio is at a relative average of 1.05, which was for more oriented investors

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.